- Home
- SNTG vs PPBT Comparison
SNTG vs PPBT Comparison
Compare SNTG & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNTG | PPBT |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNTG | PPBT |
|---|---|---|
| Price | $2.07 | $0.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.0K | ★ 680.8K |
| Earning Date | 04-27-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $107,507.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $0.53 |
| 52 Week High | $12.70 | $3.97 |
Technical Indicators
Market Signals| Indicator | SNTG | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 43.03 |
| Support Level | $1.87 | $0.64 |
| Resistance Level | $2.11 | $0.73 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 42.86 | 48.05 |
Price Performance
Historical ComparisonAbout SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.